Novel functions for gp78 in ER-associated degradation
gp78 在 ER 相关降解中的新功能
基本信息
- 批准号:7086231
- 负责人:
- 金额:$ 29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseParkinson&aposs diseasealpha 1 antitrypsin deficiencycell cycle proteinscystic fibrosiscytokine receptorsendoplasmic reticulumenzyme activityenzyme mechanismenzyme substrateimmunoprecipitationligasemembrane proteinsmolecular pathologyposttranslational modificationsproteasomeprotein bindingprotein degradationprotein protein interactionprotein structure functionprotein transporttissue /cell culturetransfectionubiquitin
项目摘要
DESCRIPTION (provided by applicant):
Endoplasmic reticulum-associated degradation (ERAD) is a process by which misfolded, unassembled, and some normal proteins are targeted for degradation by the ubiquitin proteasome pathway. ERAD is essential for many normal cellular processes and its dysfunctions contribute to the pathological conditions associated with Alzheimers' and Parkinson's diseases, cystic fibrosis, and al-antitrypsin-deficiency. While it is known that ERAD involves substrate ubiquitination, retrotranslocation, and proteasomal degradation, the molecular mechanisms for these events are not clear. To begin elucidating these molecular mechanisms, we have discovered that autocrine motility factor receptor, also known as gp78, is an ER-resident ubiquitin ligase (E3) required for ERAD and have now identified two additional gp78-interacting proteins: valosin-containing protein (VCP) and ubiquitin. Interaction of VCP with gp78 appears to activate VCP-polyubiquitin binding and facilitate polyubiquitinated protein degradation. Previous studies by others have shown that VCP is an essential factor for retrotranslocation. The finding of gp78 interactions with VCP and ubiquitin provides a novel avenue for elucidating the molecular mechanisms in ERAD. We hypothesize that gp78-acivated VCPpolyubiquitin binding couples substrate ubiquitination, retrotranslocation, and degradation during ERAD. To test the hypothesis, we propose the following specific aims: (1) to characterize gp78 interaction with VCP, ubc7, ubiquitin, and sec61 channel; (2) to elucidate the mechanisms by which gp78 activates VCPpolyubiquitin interaction; and (3) to evaluate the roles of gp78-activated VCP-polyubiquitin interaction in retrotranslocation and degradation of ERAD substrates. These studies will advance the current understanding of how gp78 and VCP is involved in substrate ubiquitination, retrotranslocation, and degradation during ERAD. The proposed work is consistent with this laboratory's long-term goal of understanding the molecular mechanisms of ERAD and its implications for disease pathogenesis.
描述(由申请人提供):
内质网相关降解(ERAD)是一个过程,其中错误折叠,未组装,和一些正常的蛋白质被靶向降解的泛素蛋白酶体途径。ERAD对于许多正常细胞过程是必不可少的,并且其功能障碍导致与阿尔茨海默病和帕金森病、囊性纤维化和α 1-抗胰蛋白酶缺乏症相关的病理状况。虽然已知ERAD涉及底物泛素化、逆转录转位和蛋白酶体降解,但这些事件的分子机制尚不清楚。为了开始阐明这些分子机制,我们发现自分泌运动因子受体,也称为gp 78,是ERAD所需的ER-驻留泛素连接酶(E3),并且现在已经鉴定了另外两种与gp 78相互作用的蛋白质:含valosin-containing蛋白(VCP)和泛素。VCP与gp 78的相互作用似乎激活VCP-多聚泛素结合并促进多聚泛素化蛋白降解。其他人的先前研究表明VCP是逆易位的必要因素。gp 78与VCP和泛素相互作用的发现为阐明ERAD的分子机制提供了新的途径。我们假设gp 78活化的VCPpolyubiquitin结合偶联底物在ERAD过程中的泛素化、逆转位和降解。为了验证这一假设,我们提出了以下具体目标:(1)表征gp 78与VCP,ubc 7,泛素和sec 61通道的相互作用;(2)阐明gp 78激活VCP-聚泛素相互作用的机制;(3)评估gp 78激活的VCP-聚泛素相互作用在ERAD底物的逆转录和降解中的作用。这些研究将推进目前的理解gp 78和VCP是如何参与底物泛素化,retrotranslocation,并在ERAD降解。拟议的工作是符合本实验室的长期目标,了解ERAD的分子机制及其对疾病发病机制的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shengyun Fang其他文献
Shengyun Fang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shengyun Fang', 18)}}的其他基金
Pharmacologic enhancement of UBA1 activity in models of VEXAS syndrome
VEXAS 综合征模型中 UBA1 活性的药理学增强
- 批准号:
10705749 - 财政年份:2022
- 资助金额:
$ 29万 - 项目类别:
High-Content Screening to identify small molecules for refolding SOD1 mutants
高内涵筛选鉴定用于重折叠 SOD1 突变体的小分子
- 批准号:
9310821 - 财政年份:2017
- 资助金额:
$ 29万 - 项目类别:
ER stress in ethanol-induced injury to hepatocytes
乙醇诱导的肝细胞损伤中的内质网应激
- 批准号:
8954727 - 财政年份:2015
- 资助金额:
$ 29万 - 项目类别:
Novel functions for gp78 in ER-associated degradation
gp78 在 ER 相关降解中的新功能
- 批准号:
7459553 - 财政年份:2004
- 资助金额:
$ 29万 - 项目类别:
Novel functions for gp78 in ER-associated degradation
gp78 在 ER 相关降解中的新功能
- 批准号:
7263002 - 财政年份:2004
- 资助金额:
$ 29万 - 项目类别:
Novel functions for gp78 in ER-associated degradation
gp78 在 ER 相关降解中的新功能
- 批准号:
6915183 - 财政年份:2004
- 资助金额:
$ 29万 - 项目类别:
Novel functions for gp78 in ER-associated degradation
gp78 在 ER 相关降解中的新功能
- 批准号:
6823958 - 财政年份:2004
- 资助金额:
$ 29万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 29万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 29万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 29万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 29万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 29万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 29万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 29万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 29万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 29万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 29万 - 项目类别: